The development of interventional cardiology is inevitably associated with increased dose of ionising radiation for the physician.1 Additionally, physiology-guided myocardial revascularisation is supported by both European and American experts,2,3 but these procedures may increase the total procedure time in addition to increased dose of ionising radiation for the physician.

This document aims to provide an overview of the clinical and regulatory challenges faced in the use of cannabinoid-based products in medicine, without becoming a comprehensive humanity review of the literature on the medical possibilities of cannabinoids.

A brain–computer interface (BCI) measures, analyses, and translates the activity of the central nervous system (CNS) into artificial…